Abpro Holdings Receives Nasdaq Listing Extension to Enhance Compliance Efforts

BURLINGTON, Mass., Dec. 9, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP), a biotechnology firm dedicated to developing next-generation antibody therapies, has been granted a formal extension by the Nasdaq Hearings Panel. This extension allows Abpro additional time to meet the compliance requirements necessary for maintaining its listing on Nasdaq.

CEO Remarks on Compliance Strategy

“We view this extension as a recognition that our compliance plan merits continued evaluation as we work to stabilize our business and build lasting momentum,” stated Miles Suk, Chief Executive Officer and Chairman of Abpro. “We’ve taken decisive steps to position the Company for sustainable growth. With a leaner structure, access to flexible capital, and continued development support for our lead candidate ABP-102 from our partner Celltrion, we are focused on execution, delivering results for our shareholders and meaningful impact for patients.”

Key Compliance Actions and Financial Strategy

In addition to a recent reverse stock split that took effect on November 3, 2025, Abpro's roadmap for compliance includes:

• Market Transfer Application: Aiming to align with Nasdaq listing standards.
• Capital Strategy: Plans to enhance stockholders' equity, crucial for maintaining compliance.
• Access to Financing: The Company has secured access to up to $44 million in equity financing to support operations and long-term financial goals.

Strategic Progress and Future Outlook

Abpro has made substantial advancements in its operational strategies, contributing to a projected 60% reduction in operating expenses compared to the previous year. Additionally, the compliance plan includes:

• Pipeline Momentum: Lead candidate ABP-102 is on track to enter first-in-human trials in 2026.
• Innovative Platforms: Advancements in Abpro’s proprietary DiversImmune® and MultiMab™ platforms are enhancing the development of multispecific antibodies with better selectivity and safety.

Management's Commitment to Shareholders

“The fundamentals of our science remain strong, and we’re now executing a smarter, more focused operating model,” said Suk. “This extension provides the time needed to continue pursuing our plan and fulfilling the conditions required under our Nasdaq compliance timeline.”

About Abpro Holdings

Abpro’s mission focuses on improving the lives of individuals battling severe and life-threatening diseases through pioneering antibody therapies. The Company is developing a portfolio of treatments targeting HER2+ cancers, non-HER2+ gastric and liver cancer, as well as conditions like wet age-related macular degeneration and diabetic macular edema, utilizing its innovative DiversImmune® platform. Abpro is headquartered in Burlington, Massachusetts. For more information, visit www.abpro.co.

Forward-Looking Statements

This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995, including expectations regarding development timelines and the effectiveness of Abpro’s strategic plans. Words such as “may,” “will,” “expect,” “plan,” and similar expressions indicate forward-looking aspects. These statements reflect management’s current expectations based on various risks and uncertainties, which could cause actual results to differ materially. Abpro advises against placing undue reliance on these statements, which may not be updated publicly.

Investor and Media Contact

Daniel Kontoh-Boateng
DKB Partners, LLC
Tel: +1-862-213-1398
Email: dboateng@dkbpartners.net